Breaking News
Woman flies to Seattle to show how all the businesses have left their downtown...
James Freeman ILLEGAL ARREST DROPPED & HUGE LAWSUIT
Jamie Kennedy blasts LA mayoral election swing: 'Literal crime scene'
Here we go, the Los Angeles Times is admitting that yes, tens of thousands of mail in ballots...
Top Tech News
World's longest-range airliner takes to the skies
Batteries That Use Sodium Instead of Lithium Could Be Low-Cost Rival to Tesla's
Elon and SpaceX Have Made AI Training 10 Times Faster
Oklo COO Says Nuclear Waste Could Power America For 150 Years
SpaceX Announces LARGEST Starship Mission Ever! They've never done this before!
Cars Are Fast Becoming Dystopian Prison Pods...
Our Emergency Water Plan Wasn't Good Enough - So We Built This
Sodium Ion Batteries Can Reach 100 Gigawatt Per Hour Per Year Scale in 2027
Juiced Bikes proves capable electric motorcycles don't have to cost a lot
Headlight projectors turn your car into a drive-in theater
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.